One year of adjuvant trastuzumab emtansine (T-DM1) leads to an impressive 5-year invasive disease-free survival rate of 97% among women with stage I human epidermal growth factor receptor 2 ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial. Estimated ...

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back ...

Treatment with T-DXd resulted in a statistically significant and clinically meaningful improvement in IDFS vs T-DM1. Topline results were announced from a phase 3 trial comparing fam-trastuzumab ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium I alongside ...

ZURICH, March 30 (Reuters) - Roche said patients with an aggressive type of breast cancer lived longer after taking its experimental "armed antibody" drug without the disease worsening than those on a ...

Twenty-four patients who had received a median of four prior chemotherapeutic agents for metastatic disease received T-DM1 at 0.3 mg/kg to 4.8 mg/kg on an every-3-weeks schedule. Transient ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan improved invasive DFS by 53% vs. T-DM1 for patients with residual disease after ...

More than 92% of patients treated with AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium alongside ...

Charles E. Geyer Jr., M.D., professor in the Division of Malignant Hematology and Medical Oncology at the University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center and UPMC Magee-Womens ...